Jul 2026· Journal of Immunology· Vol 215· 0 citations
TL;DR
Efficient RNP-mediated knockout of surface MHC-I or TCRÉ’β in human T cells is demonstrated, and delivery of reporter mRNA and siRNA to monocytes and monocyte-derived dendritic cells for enabling transient gene expression and RNAi-mediated gene knockdown is demonstrated.
Abstract
Current intracellular delivery methods face significant limitations, including a restricted range of compatible molecules and cell types, as well as unintended alterations to cell biology. CellPore™ Transfection System addresses these limitations by using mechanoporation technology to efficiently deliver mRNAs, CRISPR-Cas9 ribonucleoproteins (RNPs), siRNAs, proteins and other molecules to the cytosol.
Recent platform enhancements, including the introduction of new cartridge sizes, have expanded compatibility to a wider range of cell types. These include unactivated and activated primary immune cells (e.g. T, NK, B and myeloid cells), hematopoietic stem and progenitor cells and pluripotent stem cells, which traditionally have been challenging to reliably engineer via conventional methods.
In the context of immunology applications, we demonstrate efficient RNP-mediated knockout of surface MHC-I (74%) or TCRÉ’β (94%) in human T cells, and TIGIT (84%), CD16 (66%), NKG2A (81%) or NKp46 (87%) in human NK cells, with minimal impact to cell viability and function. We also demonstrate delivery of reporter mRNA and siRNA to monocytes and monocyte-derived dendritic cells for enabling transient gene expression and RNAi-mediated gene knockdown.
The CellPore™ system offers a gentle and efficient method to engineer a variety of cell types with a wide range of molecules. The simple and versatile workflow makes this a valuable tool for enabling new areas of research.
n/a
Technological Innovations in Immunology (TECH)
This review provides a biologically informed roadmap for designing efficient gene delivery vectors, proposing membrane-integrated nanovesicles (NVs) as "living interfaces" for non-viral gene therapy.
Clara Baldari, Claudia Leone, G. Leccese et al.· Advanced Healthcare Material...· 0 citations
The integration of rational material design, high-throughput screening, artificial intelligence, and interdisciplinary collaboration will be essential to advance next-generation targeted in vivo mRNA cell therapies toward clinical translation.
Danyang Wang, Yumin Li, Jinfeng Deng et al.· Drug Delivery· 0 citations
Adoptive cell therapy is promising with many clinical trials, but its application efficiency is significantly influenced by individual immune microenvironments and the varied responses of different patients. Equipping adoptive cells with multifunctional modules for function enhancement and real-time efficacy readouts...
Immune regulation governs tissue regeneration through coordinated time-dependent interactions among innate and adaptive immune cells. Although protein therapeutics such as cytokines and growth factors offer high specificity, their clinical translation is limited by rapid degradation and, more critically, mismatches b...
Sheng-Hua Yang, Sheng-Chih Lu, Fu-Cian Cai et al.· ACS Applied Nano Materials· 0 citations
CD4+ T cells orchestrate adaptive immunity and strategies that enable their genetic reprogramming hold promise for treating cancer, immune dysregulation and infectious diseases such as HIV. However, current T cell engineering approaches rely heavily on ex vivo manipulation, which is labor-intensive, costly, and can alt...
Maaike De Cock, Elianne Burg, Sarah Gerlo et al.· Advanced Healthcare Material...· 0 citations